{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:16:15Z","timestamp":1787501775025,"version":"build-2736575974"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Peptidream Inc."},{"name":"Amolyt Pharma"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Acromegaly is an endocrine disorder caused by the hypersecretion of growth hormone (GH) by a benign tumor of the pituitary that leads to insulin-like growth factor-1 (IGF1) overproduction. In most patients, somatostatin analogs (SSAs), the current first-line medical therapy for acromegaly, do not normalize IGF1 levels. This study aims to investigate the pre-clinical efficacy of ALXN2420, a novel, small peptide antagonist of the growth hormone receptor (GHR), being developed as a combination therapy to SSAs to further suppress and normalize IGF1 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>In vitro and in vivo experiments were performed to investigate the efficacy of ALXN2420 in antagonizing the GHR and in reducing circulating IGF1 levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The binding affinity of ALXN2420 to GHR was determined by Surface Plasmon Resonance (SPR), and inhibition of GH-induced GHR activation was investigated in vitro in primary hepatocytes. The efficacy of ALXN2420 in suppressing IGF1 levels was evaluated in rats and dogs. The ability of ALXN2420 to reduce growth was determined in the juvenile rat model. Ultimately, the effect of combining ALXN2420 with a SSA in suppressing IGF1 was examined in rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ALXN2420 bound to the human GHR and inhibited its activation by GH in vitro. In vivo, ALXN2420 administration efficiently reduced IGF1 levels, which was associated with reduced growth in juvenile rats. Importantly, when combined with a SSA, ALXN2420 demonstrated an additive effect on IGF1 reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results support the investigation of ALXN2420 as a combination therapy for the treatment of patients with acromegaly inadequately controlled by SSAs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf043","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T08:14:58Z","timestamp":1741594498000},"page":"299-307","source":"Crossref","is-referenced-by-count":6,"title":["Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo"],"prefix":"10.1093","volume":"192","author":[{"given":"Guillaume","family":"Ravel","sequence":"first","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Ecully 69130 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0097-4609","authenticated-orcid":false,"given":"Xavier","family":"Gaume","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Ecully 69130 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corentin","family":"Berardet","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Ecully 69130 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1874-2876","authenticated-orcid":false,"given":"Cl\u00e9mentine","family":"Chalmey","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Ecully 69130 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruaki","family":"Kurasaki","sequence":"additional","affiliation":[{"name":"PeptiDream Inc , Kawasaki City, Kanagawa 210-0821 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Tomiyama","sequence":"additional","affiliation":[{"name":"PeptiDream Inc , Kawasaki City, Kanagawa 210-0821 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick C","family":"Reid","sequence":"additional","affiliation":[{"name":"PeptiDream Inc , Kawasaki City, Kanagawa 210-0821 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Duracher","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Ecully 69130 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Datta","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Aouadi","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Ecully 69130 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Culler","sequence":"additional","affiliation":[{"name":"Alexion, AstraZeneca Rare Disease , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"2025032110474853800_lvaf043-B1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2147\/IJGM.S38594","article-title":"Acromegaly: the disease, its impact on patients, and managing the burden of long-term treatment","volume":"6","author":"Adelman","year":"2013","journal-title":"Int J Gen Med"},{"issue":"11","key":"2025032110474853800_lvaf043-B2","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"issue":"11","key":"2025032110474853800_lvaf043-B3","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/S2213-8587(22)00244-3","article-title":"Acromegaly: pathogenesis, diagnosis, and management","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2025032110474853800_lvaf043-B4","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025032110474853800_lvaf043-B5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"10","key":"2025032110474853800_lvaf043-B6","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025032110474853800_lvaf043-B7","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1530\/EJE-08-0843","article-title":"Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients","volume":"160","author":"Neggers","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"14","key":"2025032110474853800_lvaf043-B8","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1021\/ja312579u","article-title":"TRAP display: a high-speed selection method for the generation of functional polypeptides","volume":"135","author":"Ishizawa","year":"2013","journal-title":"J Am Chem Soc"},{"issue":"6","key":"2025032110474853800_lvaf043-B9","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/nprot.2011.331","article-title":"Flexizymes for genetic code reprogramming","volume":"6","author":"Goto","year":"2011","journal-title":"Nat Protoc"},{"key":"2025032110474853800_lvaf043-B10","author":"Kashiwagi"},{"issue":"6","key":"2025032110474853800_lvaf043-B11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/oxfordjournals.molbev.a003895","article-title":"Episodic evolution of growth hormone in primates and emergence of the species specificity of human growth hormone receptor","volume":"18","author":"Liu","year":"2001","journal-title":"Mol Biol Evol"},{"key":"2025032110474853800_lvaf043-B12","author":"Drug Approval Package: Somavert (pegvisomant) NDA#021106"},{"issue":"4","key":"2025032110474853800_lvaf043-B13","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1210\/jcem.86.4.7403","article-title":"Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer","volume":"86","author":"Ross","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2025032110474853800_lvaf043-B14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/978-3-642-10324-7_2","article-title":"Species differences in pharmacokinetics and pharmacodynamics","volume":"199","author":"Toutain","year":"2010","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"2025032110474853800_lvaf043-B15","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1210\/js.2016-1004","article-title":"Somatotroph-specific aip-deficient mice display pretumorigenic alterations in cell-cycle signaling","volume":"1","author":"Gillam","year":"2017","journal-title":"J Endocr Soc"},{"issue":"7","key":"2025032110474853800_lvaf043-B16","doi-asserted-by":"publisher","first-page":"110137","DOI":"10.1016\/j.isci.2024.110137","article-title":"Excess endocrine growth hormone in acromegaly promotes the aggressiveness and metastasis of triple-negative breast cancer","volume":"27","author":"Kang","year":"2024","journal-title":"iScience"},{"issue":"1","key":"2025032110474853800_lvaf043-B17","doi-asserted-by":"publisher","first-page":"16298","DOI":"10.1038\/srep16298","article-title":"Molecular characterization of growth hormone-producing tumors in the GC rat model of acromegaly","volume":"5","author":"Mart\u00edn-Rodr\u00edguez","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"2025032110474853800_lvaf043-B18","doi-asserted-by":"publisher","first-page":"K37","DOI":"10.1093\/ejendo\/lvae016","article-title":"Long-term depot specific changes in adipose tissue after treatment of acromegaly","volume":"190","author":"Falch","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025032110474853800_lvaf043-B19","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvab004","article-title":"Body composition changes with long-term pegvisomant therapy of acromegaly","volume":"5","author":"Kuker","year":"2021","journal-title":"J Endocr Soc"},{"issue":"5","key":"2025032110474853800_lvaf043-B20","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1530\/EJE-10-0640","article-title":"Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery","volume":"163","author":"Rubeck","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025032110474853800_lvaf043-B21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-10-0969","article-title":"Hypothesis: extra-hepatic acromegaly: a new paradigm?","volume":"164","author":"Neggers","year":"2011","journal-title":"Eur J Endocrinol"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvaf043\/62377424\/lvaf043.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/3\/299\/62377424\/lvaf043.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/192\/3\/299\/62377424\/lvaf043.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T01:14:31Z","timestamp":1742692471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/192\/3\/299\/8069785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf043","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}